Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Accounts Payables: 2023-2024

Historic Accounts Payables for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $17.1 million.

  • Zenas BioPharma's Accounts Payables fell 57.27% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 57.27%. This contributed to the annual value of $17.1 million for FY2024, which is 217.57% up from last year.
  • Per Zenas BioPharma's latest filing, its Accounts Payables stood at $17.1 million for FY2024, which was up 217.57% from $5.4 million recorded in FY2023.
  • Zenas BioPharma's Accounts Payables' 5-year high stood at $17.1 million during FY2024, with a 5-year trough of $5.4 million in FY2023.
  • Over the past 2 years, Zenas BioPharma's median Accounts Payables value was $11.3 million (recorded in 2023), while the average stood at $11.3 million.
  • Data for Zenas BioPharma's Accounts Payables shows a peak YoY surged of 217.57% (in 2024) over the last 5 years.
  • Over the past 2 years, Zenas BioPharma's Accounts Payables (Yearly) stood at $5.4 million in 2023, then skyrocketed by 217.57% to $17.1 million in 2024.